Trade Graphite Bio, Inc. - GRPH CFD

Add to favourite

2.24

0.89%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow
Ownership

Trading Conditions

Spread

0.05

Long position overnight fee

-0.026235%

Short position overnight fee

0.004012%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Graphite Bio Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	2.26
Open*	2.23
1-Year Change*	-35.36%
Day's Range*	2.21 - 2.25
52 wk Range	1.59-3.64
Average Volume (10 days)	203.93K
Average Volume (3 months)	2.69M
Market Cap	134.55M
P/E Ratio	-100.00K
Shares Outstanding	58.00M
Revenue	N/A
EPS	-2.24
Dividend (Yield %)	N/A
Beta	-100.00K
Next Earnings Date	N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Dec 1, 2023	2.24	0.01	0.45%	2.23	2.25	2.17
Nov 30, 2023	2.26	0.09	4.15%	2.17	2.27	2.17
Nov 29, 2023	2.23	0.00	0.00%	2.23	2.29	2.17
Nov 28, 2023	2.23	-0.07	-3.04%	2.30	2.33	2.16
Nov 27, 2023	2.34	0.05	2.18%	2.29	2.37	2.29
Nov 24, 2023	2.29	0.01	0.44%	2.28	2.34	2.28
Nov 22, 2023	2.29	0.00	0.00%	2.29	2.33	2.23
Nov 21, 2023	2.31	0.01	0.43%	2.30	2.40	2.28
Nov 20, 2023	2.32	0.06	2.65%	2.26	2.36	2.26
Nov 17, 2023	2.30	0.06	2.68%	2.24	2.31	2.23
Nov 16, 2023	2.23	0.09	4.21%	2.14	2.27	2.14
Nov 15, 2023	2.24	0.10	4.67%	2.14	2.27	2.00
Nov 14, 2023	2.30	0.02	0.88%	2.28	2.34	2.26
Nov 13, 2023	2.28	0.01	0.44%	2.27	2.30	2.24
Nov 10, 2023	2.31	0.04	1.76%	2.27	2.32	2.25
Nov 9, 2023	2.32	0.02	0.87%	2.30	2.37	2.27
Nov 8, 2023	2.36	0.03	1.29%	2.33	2.41	2.30
Nov 7, 2023	2.38	0.06	2.59%	2.32	2.41	2.32
Nov 6, 2023	2.39	0.10	4.37%	2.29	2.42	2.21
Nov 3, 2023	2.27	-0.08	-3.40%	2.35	2.38	2.27

Graphite Bio, Inc. Events

Time (UTC)	Country	Event
No events scheduled

View all events

Annual
Quarterly

	2022	2021	2020	2019
Total revenue	0	0	0	0
Total Operating Expense	105.639	60.443	13.5	0.029
Selling/General/Admin. Expenses, Total	32.852	22.511	4.377	0.029
Research & Development	72.787	37.932	9.123	0
Operating Income	-105.639	-60.443	-13.5	-0.029
Interest Income (Expense), Net Non-Operating		0	-0.04	-0.08
Other, Net	4.587	-10.317	-54.833	0
Net Income Before Taxes	-101.052	-70.76	-68.373	-0.109
Net Income After Taxes	-101.052	-70.76	-68.373	-0.109
Net Income Before Extra. Items	-101.052	-70.76	-68.373	-0.109
Net Income	-101.052	-70.76	-68.373	-0.109
Income Available to Common Excl. Extra. Items	-101.052	-70.76	-68.373	-0.109
Income Available to Common Incl. Extra. Items	-101.052	-70.76	-68.373	-0.109
Diluted Net Income	-101.052	-70.76	-68.373	-0.109
Diluted Weighted Average Shares	54.8737	28.9193	58.079	58.079
Diluted EPS Excluding Extraordinary Items	-1.84154	-2.44681	-1.17724	-0.00188
Dividends per Share - Common Stock Primary Issue			0	0
Diluted Normalized EPS	-1.84154	-2.44681	-1.17724	-0.00188

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0	0	0
Total Operating Expense	58.159	26.45	26.751	26.154	26.776
Selling/General/Admin. Expenses, Total	7.455	7.623	8.289	7.852	8.999
Research & Development	13.508	16.244	18.462	18.302	17.777
Operating Income	-58.159	-26.45	-26.751	-26.154	-26.776
Interest Income (Expense), Net Non-Operating
Other, Net	2.845	2.587	2.152	1.472	0.84
Net Income Before Taxes	-55.314	-23.934	-24.599	-24.682	-25.936
Net Income After Taxes	-55.314	-23.934	-24.599	-24.682	-25.936
Net Income Before Extra. Items	-55.314	-23.934	-24.599	-24.682	-25.936
Net Income	-55.314	-23.934	-24.599	-24.682	-25.936
Income Available to Common Excl. Extra. Items	-55.314	-23.934	-24.599	-24.682	-25.936
Income Available to Common Incl. Extra. Items	-55.314	-23.934	-24.599	-24.682	-25.936
Diluted Net Income	-55.314	-23.934	-24.599	-24.682	-25.936
Diluted Weighted Average Shares	56.7453	55.8645	55.7199	55.2061	54.5729
Diluted EPS Excluding Extraordinary Items	-0.97478	-0.42843	-0.44148	-0.44709	-0.47525
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.31929	-0.38092	-0.44148	-0.44709	-0.47525
Unusual Expense (Income)	37.196	2.583
Gain (Loss) on Sale of Assets	0	-0.071

Annual
Quarterly

	2022	2021	2020	2019
Total Current Assets	275.365	381.736	21.103	0.006
Cash and Short Term Investments	268.229	376.976	19.782	0.006
Cash & Equivalents	47.73	376.976	19.782	0.006
Prepaid Expenses	7.136	4.76	1.286	0
Other Current Assets, Total		0	0.035	0
Total Assets	321.902	401.987	22.564	0.006
Property/Plant/Equipment, Total - Net	28.21	18.081	1.461	0
Total Current Liabilities	13.043	12.143	32.048	2.224
Accounts Payable	2.608	2.453	0.63	0
Accrued Expenses	10.435	9.69	2.356	0.019
Notes Payable/Short Term Debt	0	0	0	2.205
Other Current Liabilities, Total		0	29.062	0
Total Liabilities	25.611	17.937	32.364	2.224
Total Long Term Debt	0	0	0	0
Other Liabilities, Total	12.568	5.794	0.316	0
Total Equity	296.291	384.05	-9.8	-2.218
Redeemable Preferred Stock	0	0	55.608	0
Common Stock	0.001	0.001	0	0
Additional Paid-In Capital	539.741	525.4	5.183	0
Retained Earnings (Accumulated Deficit)	-242.403	-141.351	-70.591	-2.218
Total Liabilities & Shareholders’ Equity	321.902	401.987	22.564	0.006
Total Common Shares Outstanding	58.2218	58.0108	58.079	58.079
Property/Plant/Equipment, Total - Gross	31.417	18.936	1.582
Accumulated Depreciation, Total	-3.207	-0.855	-0.121
Other Long Term Assets, Total	3.005	2.17
Short Term Investments	220.499
Long Term Investments	15.322
Other Equity, Total	-1.048

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	238.783	251.171	270.307	275.365	298.492
Cash and Short Term Investments	233.986	246.665	264.096	268.229	291.685
Cash & Equivalents	182.988	128.506	69.811	47.73	56.391
Prepaid Expenses	4.777	2.878	6.211	7.136	6.807
Other Current Assets, Total	0.02	1.628
Total Assets	266.228	287.044	309.996	321.902	334.845
Property/Plant/Equipment, Total - Net	25.729	33.802	37.084	28.21	20.39
Property/Plant/Equipment, Total - Gross	26.567	37.077	40.946	31.417	22.915
Accumulated Depreciation, Total	-0.838	-3.275	-3.862	-3.207	-2.525
Other Long Term Assets, Total	1.716	2.071	2.605	3.005	2.56
Total Current Liabilities	12.537	12.27	14.341	13.043	13.524
Accounts Payable	3.753	2.72	1.992	2.608	3.972
Accrued Expenses	8.784	9.55	12.349	10.435	9.552
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total
Total Liabilities	62.209	62.898	33.772	25.611	18.392
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	49.672	50.628	19.431	12.568	4.868
Total Equity	204.019	224.146	276.224	296.291	316.453
Redeemable Preferred Stock	0	0	0	0	0
Common Stock	0.001	0.001	0.001	0.001	0.001
Additional Paid-In Capital	548.249	546.067	543.029	539.741	535.852
Retained Earnings (Accumulated Deficit)	-344.136	-321.651	-266.337	-242.403	-217.804
Total Liabilities & Shareholders’ Equity	266.228	287.044	309.996	321.902	334.845
Total Common Shares Outstanding	57.9719	57.9893	58.1948	58.2218	58.1493
Short Term Investments	50.998	118.159	194.285	220.499	235.294
Long Term Investments	0	0	0	15.322	13.403
Other Equity, Total	-0.095	-0.271	-0.469	-1.048	-1.596

Annual
Quarterly

	2022	2021	2020	2019
Net income/Starting Line	-101.052	-70.76	-68.373	-0.109
Cash From Operating Activities	-87.98	-52.852	-8.721	-0.019
Cash From Operating Activities	2.352	0.734	0.121	0
Non-Cash Items	17.928	19.672	57.822	0.08
Changes in Working Capital	-7.208	-2.498	1.709	0.01
Cash From Investing Activities	-241.863	-5.74	-1.545	0
Capital Expenditures	-6.594	-5.74	-1.545	0
Cash From Financing Activities	0.597	417.467	30.077	0
Issuance (Retirement) of Stock, Net	0.676	417.467	25.077	0
Issuance (Retirement) of Debt, Net		0	5	0
Net Change in Cash	-329.246	358.875	19.811	-0.019
Other Investing Cash Flow Items, Total	-235.269
Financing Cash Flow Items	-0.079

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-23.934	-101.052	-76.453	-51.771	-25.835
Cash From Operating Activities	-21.074	-87.98	-65.551	-43.334	-21.24
Cash From Operating Activities	0.654	2.352	1.67	1.018	0.44
Non-Cash Items	3.267	17.928	13.887	9.723	4.839
Changes in Working Capital	-1.061	-7.208	-4.655	-2.304	-0.684
Cash From Investing Activities	43.163	-241.863	-255.387	-258.883	-170.666
Capital Expenditures	-0.383	-6.594	-5.573	-4.658	-3.273
Cash From Financing Activities	-0.008	0.597	0.353	0.412	0
Financing Cash Flow Items	-0.008	-0.079	-0.079	-0.015	0
Issuance (Retirement) of Stock, Net		0.676	0.432	0.427	0
Net Change in Cash	22.081	-329.246	-320.585	-301.805	-191.906
Issuance (Retirement) of Debt, Net
Other Investing Cash Flow Items, Total	43.546	-235.269	-249.814	-254.225	-167.393

Investor Name	Investor Type	Percent Outstanding	Shares Held	Shares change	Holdings Date	Turnover Rating
Versant Ventures	Venture Capital	28.3133	16416117	0	2023-03-31	LOW
EcoR1 Capital, LLC	Hedge Fund	14.7265	8538446	0	2023-06-30	LOW
Samsara BioCapital, LLC	Venture Capital	14.59	8459314	0	2023-06-30	LOW
Porteus (Matthew)	Individual Investor	6.0857	3528529	0	2023-03-31	LOW
Tang Capital Management, LLC	Hedge Fund	3.5971	2085625	57159	2023-06-30	MED
Prosight Capital	Hedge Fund	2.932	1700000	823334	2023-06-30	HIGH
BlackRock Institutional Trust Company, N.A.	Investment Advisor	2.6468	1534623	1064173	2023-06-30	LOW
The Vanguard Group, Inc.	Investment Advisor/Hedge Fund	2.3795	1379642	145204	2023-06-30	LOW
Citadel Advisors LLC	Hedge Fund	2.0771	1204295	33118	2023-06-30	LOW
Lehrer-Graiwer (Joshua)	Individual Investor	2.0036	1161670	0	2023-03-31	LOW
Stanford Management Company	Endowment Fund	1.2126	703071	0	2023-06-30
Geode Capital Management, L.L.C.	Investment Advisor/Hedge Fund	0.8937	518170	270790	2023-06-30	LOW
State Street Global Advisors (US)	Investment Advisor/Hedge Fund	0.7605	440967	351816	2023-06-30	LOW
Federated Hermes Global Investment Management Corp.	Investment Advisor/Hedge Fund	0.7008	406308	0	2023-06-30	LOW
OUP Management Co., LLC	Venture Capital	0.7008	406308	0	2023-06-30	LOW
Two Sigma Investments, LP	Hedge Fund	0.5643	327204	-25292	2023-06-30	HIGH
Gutry (Phil)	Individual Investor	0.5577	323355	24884	2023-03-31	LOW
Privium Fund Management (UK) Ltd	Investment Advisor	0.4534	262858	-18903	2023-06-30	HIGH
Renaissance Technologies LLC	Hedge Fund	0.421	244100	15900	2023-06-30	HIGH
Bellecapital Partners AG	Investment Advisor/Hedge Fund	0.4104	237944	0	2023-02-28	LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Graphite Bio, Inc. Company profile

About Graphite Bio Inc

Graphite Bio, Inc. is clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. The Company's gene editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. The Company's pipeline includes multiple programs including its gene replacement program, GPH201 for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene prevent normal immune system function, and targeted gene insertion program, GPH301 for Gaucher disease, and multiple additional programs in both HSCs and other cell types.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Graphite Bio Inc revenues was not reported. Net loss increased 3% to $70.8M. Higher net loss reflects Research and development - Balancing val increase from $9M to $35.2M (expense), General and administrative - Balancing v increase from $4.3M to $17.3M (expense), Stock-based Compensation in SGA increase from $54K to $5.2M (expense).

Industry:

Bio Therapeutic Drugs

611 Gateway Blvd, Suite 120
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

Annual
Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023